Schizophrenia Research
Volume 92, Issue 1 , Pages 90-94 , May 2007

Risperidone augmentation for schizophrenia partially responsive to clozapine: A double-blind, placebo-controlled trial

  • Oliver Freudenreich

      Affiliations

    • Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, 25 Staniford St., 2nd Floor, Boston, MA 02114, United States
    • Harvard Medical School, Boston, MA, United States
    • Boston University School of Medicine, Boston, MA, United States
    • Corresponding Author InformationCorresponding author. MGH Schizophrenia Program, Freedom Trail Clinic, 25 Staniford St., 2nd Floor, Boston, MA 02114, United States. Tel.: +1 617 912 7835; fax: +1 617 723 3919.
    • ,
  • David C. Henderson

      Affiliations

    • Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, 25 Staniford St., 2nd Floor, Boston, MA 02114, United States
    • Harvard Medical School, Boston, MA, United States
    • ,
  • Jared P. Walsh

      Affiliations

    • Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, 25 Staniford St., 2nd Floor, Boston, MA 02114, United States
    • ,
  • Melissa A. Culhane

      Affiliations

    • Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, 25 Staniford St., 2nd Floor, Boston, MA 02114, United States
    • Harvard Medical School, Boston, MA, United States
    • ,
  • Donald C. Goff

      Affiliations

    • Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, 25 Staniford St., 2nd Floor, Boston, MA 02114, United States
    • Harvard Medical School, Boston, MA, United States

Received 6 October 2006 ,Revised 14 December 2006 ,Accepted 20 December 2006.

References 

  1. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenia. Schizophr. Res. 1990;3:247–251
  2. American Psychiatric Association Committee on Nomenclature and Statistics . Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington, DC: American Psychiatric Association; 1994;
  3. Andreasen NC. Negative symptoms in schizophrenia: definition and reliability. Arch. Gen. Psychiatry. 1982;39:784–788
  4. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: University of Iowa; 1983;
  5. Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, Tumuklu M, Yazici MK, Alptekin K, et al A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J. Clin. Psychiatry. 2005;66:63–72
  6. Barnes TRE. A rating scale for drug-induced akathisia. Br. J. Psychiatry. 1989;154:672–676
  7. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr. Scand. 2002;106:323–330
  8. Guy, W., 1976. ECDEU Assessment manual for psychopharmacology — revised (DHEW Publ No ADM 76–338). Rockville, MD: U.S. Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs. 534–537 p.
  9. Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J. Clin. Psychiatry. 1996;57:395–397
  10. Honer WG, Thornton AE, Chen EYH, Chan RCK, Wong JOY, Bergman A, et al Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N. Engl. J. Med. 2006;354:472–482
  11. Josiassen RC, Joseph A, Kohegyi E, Stokes S, Dadvand M, Wynn Paing W, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am. J. Psychiatry. 2005;162:130–136
  12. Kapur S, Roy P, Daskalakis J, Remington G, Zipursky R. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am. J. Psychiatry. 2001;158:311–314
  13. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13:261–276
  14. Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, Paplos KG, Pappa DA, Christodoulou GN. Risperidone augmentation of clozapine: a critical review. Eur. Arch. Psychiatry Clin. Neurosci. 2006;256:350–355
  15. Kraemer HC, Mintz J, Noda A, Tinklenberg J, Yesavage JA. Caution regarding the use of pilot studies to guide power calculations for study proposals. Arch. Gen. Psychiatry. 2006;63:484–489
  16. Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol. Bull. 1986;22:343–381
  17. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J. Clin. Psychiatry. 1997;58:538–546
  18. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. 1970;212:11–19
  19. Taylor CG, Flynn SW, Altman S, Ehmann T, MacEwan GW, Honer WG. An open trial of risperidone augmentation of partial response to clozapine. Schizophr. Res. 2001;48:155–158
  20. VanderZwaag C, McGee M, McEvoy JP, Freudenreich O, Wilson WH, Cooper TB. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am. J. Psychiatry. 1996;153:1579–1584

☆ Funding for this trial was provided by a grant from the Stanley Medical Research Institute (Oliver Freudenreich).

PII: S0920-9964(07)00032-1

doi: 10.1016/j.schres.2006.12.030

Schizophrenia Research
Volume 92, Issue 1 , Pages 90-94 , May 2007

Article Tools

* Image Usage & Resolution